Compare Sanofi SA (SNY) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs ProShares Ultra Gold ETF — how do they compare? Sanofi SA trades at $43.61 (market cap $104.30B), while ProShares Ultra Gold ETF trades at $51.98. The key difference: Sanofi SA pays a 5.55% dividend while ProShares Ultra Gold ETF pays none, and ProShares Ultra Gold ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | UGL | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $85.62 |
52-Week Low | $41.33 | $34.37 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
UGL is trading at $52.81, up 2.13% with a bullish technical signal from moving averages, though oscillators show bearish divergence. The stock faces resistance at $53 with support at $51. Recent gold market strength from inflation data and geopolitical tensions provides positive momentum, though financial ratios remain unavailable for fundamental assessment.
The outlook for UGL appears cautiously optimistic given gold's recent performance, but investment decisions require verified financial data currently missing. Key risks include gold price volatility and reliance on broader commodity trends. Analyst consensus and institutional positioning data are needed for comprehensive evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
